Tumor Genomics, Individual Risk Factors, and External Drivers of Health on Health Outcomes for Patients With Meningioma

An Investigation of Tumor Genomics, Individual Risk Factors, and External Drivers of Health to Improve Health Outcomes for Patients With Meningioma

Meningiomas are the most common primary brain tumor, and some groups are diagnosed with higher-grade tumors and have clinically worse outcomes. This study investigates social determinants of health and individual risk factors that may be associated with meningioma.

Study Overview

• Status: Recruiting
• Conditions: Brain Tumor; Meningioma; Meningioma of Brain
• Intervention / Treatment: Behavioral: Questionnaire; Other: Medical Record Review

Detailed Description

PRIMARY OBJECTIVES:

I. To assess prevalence and distribution of social and structural determinants of health (SSDH) among meningioma patients.

II. To assess disparities in SSDH among meningioma patients of different races.

OUTLINE: This is an observational study.

Participants will complete a survey and have their medical records reviewed.

• Study Type: Observational
• Enrollment (Estimated): 3000

Contacts and Locations

• Study Contact: Name: Zora Arum; Phone Number: 877-827-3222; Email: zora.arum2@ucsf.edu

Study Locations

• United States
  • California
    • San Francisco, California, United States, 94143
      • Recruiting
      • University of California San Francisco
      • Contact: Phone Number: 877-827-3222; Email: cancertrials@ucsf.edu
      • Contact: Zora Arum; Phone Number: 877-827-3222; Email: zora.arum2@ucsf.edu
      • Principal Investigator: David Raleigh, MD PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

Adult participants receiving care at the University of California, San Francisco who have been diagnosed with meningioma.

Description

Inclusion Criteria:

• Adults ≥18 years of age
• Able to speak and read English
• Diagnosed with a meningioma

Exclusion Criteria:

• Active psychiatric issues (suicidality, active psychosis, grave disability, etc.)
• Inability to consent secondary to severe neurologic deficit or psychiatric distress
• Inability to complete survey secondary to severe neurologic deficit or psychiatric distress

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Participants with Meningioma; Adult patients who have been diagnosed with a meningioma will be asked to complete a one-time survey, which will take roughly 20 minutes to complete. Participants will also have medical records reviewed to capture additional data relating to the participants medical history.	Behavioral: Questionnaire; A questionnaire will be administered in person or online; Other: Medical Record Review; Medical records will be reviewed for study specific data collection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Identifying potential social and structural determinants of health (SSDH)	The prevalence of SSDH factors such as race and ethnicity, birthplace, relationship status, sexual orientation/gender identity, education level, socio-economic status, access to care, reproductive/menstrual history, health factors and medication use, chemical and radiation exposure, smoking history, and perceived stress for participants with meningioma will be analyzed using multilevel logistic and linear models accounting for geographical clustering.	Up to 5 years
Distribution of social and structural determinants of health	The distribution of SSDH factors across racial groups will be analyzed using multilevel logistic and linear models accounting for geographical clustering.	Up to 5 years
Identify disparities in social and structural determinants of health (SSDH)	Disparities of SSDH factors across racial groups will be analyzed using multilevel logistic and linear models accounting for geographical clustering.	Up to 5 years

Collaborators and Investigators

• Sponsor: University of California, San Francisco
• Collaborators: National Cancer Institute (NCI)
• Investigators: Principal Investigator: David Raleigh, MD, PhD, University of California, San Francisco, San Francisco, California 94143

Study record dates

Study Major Dates

• Study Start (Actual): January 16, 2026
• Primary Completion (Estimated): January 1, 2031
• Study Completion (Estimated): January 1, 2032

Study Registration Dates

• First Submitted: February 11, 2026
• First Submitted That Met QC Criteria: February 11, 2026
• First Posted (Actual): February 18, 2026

Study Record Updates

• Last Update Posted (Actual): May 19, 2026
• Last Update Submitted That Met QC Criteria: May 15, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neoplasms by Site; Neoplasms; Neoplasms by Histologic Type; Neoplasms, Nerve Tissue; Nervous System Neoplasms; Neoplasms, Vascular Tissue; Meningeal Neoplasms; Central Nervous System Neoplasms; Meningioma; Brain Neoplasms; Health Care Quality, Access, and Evaluation; Investigative Techniques; Epidemiologic Methods; Data Collection; Health Care Evaluation Mechanisms; Quality of Health Care; Public Health; Environment and Public Health; Surveys and Questionnaires
• Other Study ID Numbers: 25109; NCI-2026-00576 (Registry Identifier: NCI Clinical Trials Reporting System (CTRP)); 1U54CA302452-01 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No